Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Malaria Research and Training Center, Bamako, Mali | OTHER |
| University of Washington | OTHER |
| Harvard School of Public Health (HSPH) | OTHER |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the safety, tolerability, and efficacy of VRC MALMAB0100-00-AB (CIS43LS), a human monoclonal antibody, against naturally occurring Plasmodium falciparum (Pf) infection.
This study will evaluate the safety, tolerability, and efficacy of VRC MALMAB0100-00-AB (CIS43LS), a human monoclonal antibody, against naturally occurring Plasmodium falciparum (Pf) infection.
The first part of the study is an open-label dose-escalation study for safety and tolerability. Participants will be assigned to one of three dose arms. Dosing will begin in the lowest dose arm. Once all participants in that arm reach Day 7 post-infusion, if no safety concerns have arisen, dosing will begin at the subsequent dose level. This process will be repeated until participants complete the third dose arm. Participants will be followed for safety to assess adverse events (AEs) at study visits 1, 3, 7, 14, 21, and 28 days after administration, then monthly through 24 weeks after administration.
After the last subject in the highest dose arm reaches Day 7 safety follow-up, an interim safety evaluation will be performed before enrollment begins for the second part of the study.
The second part of the study is a randomized, double-blind, placebo-controlled trial to assess safety and protective efficacy of CIS43LS and placebo. Participants in the efficacy study will receive the study agent and be followed at study visits 1, 3, 7, 14, 21, and 28 days later, and once every 2 weeks thereafter through 24 weeks. Primary study assessments include physical examinations and blood collection for identification of Pf infection and other research laboratory evaluations.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dose-escalation study: Arm 1: 5 mg/kg of CIS43LS | Experimental | Participants receive 5 mg/kg of CIS43LS as one time intravenous infusion on Day 0. |
|
| Dose-escalation study: Arm 2: 10 mg/kg of CIS43LS | Experimental | Participants receive 10 mg/kg of CIS43LS as one time intravenous infusion on Day 0. |
|
| Dose-escalation study: Arm 3: 40 mg/kg of CIS43LS | Experimental | Participants receive 40 mg/kg of CIS43LS as one time intravenous infusion on Day 0. |
|
| Efficacy study: Arm 1: 10 mg/kg of CIS43LS | Experimental | Participants receive 10 mg/kg of CIS43LS as one time intravenous infusion on Day 0. |
|
| Efficacy study: Arm 2: 40 mg/kg of CIS43LS | Experimental | Participants receive 40 mg/kg of CIS43LS as one time intravenous infusion on Day 0. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| VRC-MALMAB0100-00-AB (CIS43LS) | Biological | Administered via one-time intravenous infusion |
|
| Measure | Description | Time Frame |
|---|---|---|
| Participants With Local Adverse Events (AEs) | Participants with incidence of local adverse events occurring within 7 days after administration of CIS43LS. Local reactogenicity included pain/tenderness, swelling, redness, bruising, and pruritus at the site of infusion. | Within 7 days after administration of CIS43LS |
| Severity of Local Adverse Events (AEs) | The severity of local AEs was graded using the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Clinical Trials. Grade 1: Pain = does not interfere with activity; Tenderness = mild discomfort to touch; Erythema/Redness = 2.5-5 cm; Induration/Swelling = 2.5-5 cm and does not interfere with activity. Grade 2: Pain = Repeated use of non-narcotic pain reliever > 24 hours or interferes with daily activity; Tenderness = Discomfort with movement; Erythema/Redness = 5.1-10 cm; Induration/Swelling = 5.1-10 cm and interferes with activity. Grade 3: Pain = Any use of narcotic pain reliever or prevents daily activity; Tenderness = Significant discomfort at rest; Erythema/Redness = > 10 cm; Induration/Swelling = > 10 cm or prevents daily activity. Grade 4: Pain = Emergency room (ER) visit or hospitalization; Tenderness = ER visit or hospitalization; Erythema/Redness = Necrosis or exfoliative dermatitis; Induration/Swelling = Necrosis Grade 5: Death | Within 7 days after the administration of CIS43LS |
| Participants With Systemic Adverse Events (AEs) | Participants with incidence of systemic adverse events occurring within 7 days after product administration of CIS43LS. Systemic reactogenicity events included fever, feeling unusually tired or unwell, muscle aches, headache, chills, nausea, and joint pain. | Within 7 days after the administration of CIS43LS |
| Severity of Systemic Adverse Events (AEs) | The severity of systemic AEs occurring after the administration of CIS43LS was assessed using the grading scale below: Grade 1: Fever = 37.5^oC-37.9^oC; Fatigue, Headache, Myalgia = No interference with activity; Nausea = no interference with activity or 1-2 episodes/hour Grade 2: Fever = 38^oC-38.4^oC; Fatigue, Myalgia = Some interference with activity; Headache = Repeated use of non-narcotic pain reliever > 24 hours or some interference with activity; Nausea = Some interference with activity or > 2 episodes/24 hours Grade 3: Fever = 38.5^oC-39.5^oC; Fatigue = Prevents daily activity; Headache =Significant; any use of narcotic pain reliever or prevents daily activity; Myalgia =Significant; prevents daily activity; Nausea = Prevents daily activity, requires outpatient intravenous hydration Grade 4: Fever = > 39.5^oC; Fatigue, Headache, Myalgia = Emergency room (ER) visit or hospitalization; Nausea = ER visit or hospitalization for hypotensive shock Grade 5: Death |
| Measure | Description | Time Frame |
|---|---|---|
| Participants With Plasmodium Falciparum (Pf) Infection Detected by Reverse Transcription Polymerase Chain Reaction (RT-PCR) | Number of participants with Plasmodium falciparum (Pf) blood stage infection defined as blood smear-positive for Pf was assessed by reverse transcription polymerase chain reaction (RT-PCR) using dried blood spot specimen collected from participants from day 21 through week 24 (168 days) after administration of CIS43LS or placebo. Sample was collected every two weeks until 24 weeks. Plasmodium 18S rRNA RT-PCR assay was applied to dried blood spots during analysis. |
Not provided
Inclusion Criteria:
Aged ≥18 and ≤55 years.
Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
In good general health and without clinically significant medical history.
Able to provide informed consent.
Willing to have blood samples and data stored for future research.
Resides in or near Kalifabougou or Torodo, Mali, and available for the duration of the study.
Females of childbearing potential must be willing to use reliable contraception from 21 days prior to study day 0 through the final study visit as described below.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kassoum Kayentao, MD, MPH, PhD | Faculté de Médecine Pharmacie d'Odontostomatologie (FMPOS) | Principal Investigator |
| Peter D. Crompton, MD, MPH | National Institutes of Health (NIH) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kalifabougou MRTC Clinic | Kalifabougou | Koulikoro | Mali | |||
| Torodo MRTC Clinic |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36317783 | Result | Kayentao K, Ongoiba A, Preston AC, Healy SA, Doumbo S, Doumtabe D, Traore A, Traore H, Djiguiba A, Li S, Peterson ME, Telscher S, Idris AH, Kisalu NK, Carlton K, Serebryannyy L, Narpala S, McDermott AB, Gaudinski M, Traore S, Cisse H, Keita M, Skinner J, Hu Z, Zeguime A, Ouattara A, Doucoure M, Dolo A, Djimde A, Traore B, Seder RA, Crompton PD; Mali Malaria mAb Trial Team. Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali. N Engl J Med. 2022 Nov 17;387(20):1833-1842. doi: 10.1056/NEJMoa2206966. Epub 2022 Oct 31. | |
| 42407014 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Dose-escalation Study: Arm 1: 5 mg/kg of CIS43LS | Participants receive 5 mg/kg of CIS43LS as one time intravenous infusion on Day 0. |
| FG001 | Dose-escalation Study: Arm 2: 10 mg/kg of CIS43LS | Participants receive 10 mg/kg of CIS43LS as one time intravenous infusion on Day 0. |
| FG002 | Dose-escalation Study: Arm 3: 40 mg/kg of CIS43LS | Participants receive 40 mg/kg of CIS43LS as one time intravenous infusion on Day 0. |
| FG003 | Efficacy Study: Arm 1: 10 mg/kg of CIS43LS | Participants receive 10 mg/kg of CIS43LS as one time intravenous infusion on Day 0. |
| FG004 | Efficacy Study: Arm 2: 40 mg/kg of CIS43LS | Participants receive 40 mg/kg of CIS43LS as one time intravenous infusion on Day 0. |
| FG005 | Efficacy Study: Arm 3: Placebo | Participants receive placebo as one time intravenous infusion on Day 0. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation Study - 5 mg/kg |
| |||||||||||||
| Dose Escalation Study - 10 mg/kg |
| |||||||||||||
| Dose Escalation Study - 40 mg/kg |
| |||||||||||||
| Efficacy Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Dose-escalation Study: Arm 1: 5 mg/kg of CIS43LS | Participants receive 5 mg/kg of CIS43LS as one time intravenous infusion on Day 0. |
| BG001 | Dose-escalation Study: Arm 2: 10 mg/kg of CIS43LS |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Participants With Local Adverse Events (AEs) | Participants with incidence of local adverse events occurring within 7 days after administration of CIS43LS. Local reactogenicity included pain/tenderness, swelling, redness, bruising, and pruritus at the site of infusion. | The analysis included all participants in the dose escalation study. | Posted | Count of Participants | Participants | Within 7 days after administration of CIS43LS |
|
Up to 24 weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Dose-escalation Study: Arm 1: 5 mg/kg of CIS43LS | Participants receive 5 mg/kg of CIS43LS as one time intravenous infusion on Day 0. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Appendectomy | Surgical and medical procedures | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Peter Crompton | National Institute of Allergy and Infectious Diseases (NIAID) | 301-761-5042 | pcrompton@niaid.nih.gov |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Oct 13, 2022 | Mar 21, 2024 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D008288 | Malaria |
| ID | Term |
|---|---|
| D011528 | Protozoan Infections |
| D010272 | Parasitic Diseases |
| D007239 | Infections |
| D000096724 | Mosquito-Borne Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000719153 | CIS43LS |
| D000077330 | Saline Solution |
| ID | Term |
|---|---|
| D000077324 | Crystalloid Solutions |
| D007552 | Isotonic Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Efficacy study: Arm 3: Placebo | Placebo Comparator | Participants receive placebo as one time intravenous infusion on Day 0. |
|
| Normal saline | Other | Administered via one-time intravenous infusion |
|
| Within 7 days after the administration of CIS43LS |
| Participants With Plasmodium Falciparum (Pf) Infection Detected by Microscopic Examination | Number of participants with Plasmodium falciparum (Pf) blood stage infection defined as blood smear-positive for Pf was assessed by microscopic examination of thick blood smear collected from participants from day 7 through week 24 (168 days) after administration of CIS43LS or placebo. Sample was collected every two weeks until week 24. | Day 7 through week 24 (168 days) after administration of intervention |
| Day 21 through week 24 (168 days) after administration of intervention |
| Maximum Serum Concentration (Cmax) for CIS43LS | Maximum serum concentration (Cmax) of CIS43LS by dose group following a single intravenous administration to assess durability of CIS43LS and allow for correlation with Plasmodium falciparum (Pf) infection risk. Cmax is the peak serum concentration that CIS43LS achieves after it has been administered. It is determined as a maximum value on the summary pharmacokinetic (PK) curve for each study group and measured by a Meso Scale Discovery LLC-based automation platform. | Measured through Week 24 |
| Time to Maximum Serum Concentration (Tmax) for CIS43LS | Time to maximum total serum concentration (Cmax) of CIS43LS by dose group following a single intravenous administration. Tmax is the time it takes to reach Cmax of CIS43LS after it has been administered; it is determined based on the summary PK curve for each dose group. This was calculated by subtracting the time the CIS43LS intravenous infusion was stopped from the time the blood was collected for the Cmax, at the post-one hour blood draw. | One to 24 hours post-infusion |
| Torodo |
| Koulikoro |
| Mali |
| Derived |
| Tran TM, Hu Z, Kayentao K, Ongoiba A, Jones S, Abla N, Healy SA, Cisse H, Chang BH, Skinner J, Serebryannyy L, Narpala SR, Schlesinger R, Low KH, Kazmierski R, Lin BC, Dias J, Doumbo S, Doumtabe D, Preston AC, Li S, Peterson ME, Oberai A, Shandling AD, Campo JJ, Murphy SC, Telscher S, Coates EE, Capparelli EV, Dolo A, Traore B, Seder RA, Crompton PD. Pharmacokinetics and pharmacodynamics of a long-acting monoclonal antibody against malaria in African adults. J Clin Invest. 2026 Jul 2:e207559. doi: 10.1172/JCI207559. Online ahead of print. |
| 40461818 | Derived | Skinner J, Kayentao K, Ongoiba A, Healy SA, Hu Z, Preston AC, Niangaly A, Schwabl P, Cisse H, Doumbo S, Doumtabe D, Traore A, Li S, Peterson ME, Seilie AM, Chavtur C, Staubus W, Chang M, Kelley K, Traore H, Djiguiba A, Keita M, Ouattara A, Doucoure M, Keita M, Diarra D, Sylla M, Diakite D, Konate M, Traore S, Zeguime A, Dolo A, Neafsey DE, Murphy SC, Traore B, Seder RA, Crompton PD. Anti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trial. Nat Med. 2025 Aug;31(8):2682-2690. doi: 10.1038/s41591-025-03739-y. Epub 2025 Jun 3. |
| COMPLETED |
|
| NOT COMPLETED |
|
| COMPLETED |
|
| NOT COMPLETED |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
Participants receive 10 mg/kg of CIS43LS as one time intravenous infusion on Day 0.
| BG002 | Dose-escalation Study: Arm 3: 40 mg/kg of CIS43LS | Participants receive 40 mg/kg of CIS43LS as one time intravenous infusion on Day 0. |
| BG003 | Efficacy Study: Arm 1: 10 mg/kg of CIS43LS | Participants receive 10 mg/kg of CIS43LS as one time intravenous infusion on Day 0. |
| BG004 | Efficacy Study: Arm 2: 40 mg/kg of CIS43LS | Participants receive 40 mg/kg of CIS43LS as one time intravenous infusion on Day 0. |
| BG005 | Efficacy Study: Arm 3: Placebo | Participants receive placebo as one time intravenous infusion on Day 0. |
| BG006 | Total | Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
Participants receive 10 mg/kg of CIS43LS as one time intravenous infusion on Day 0.
| OG002 | Dose-escalation Study: Arm 3: 40 mg/kg of CIS43LS | Participants receive 40 mg/kg of CIS43LS as one time intravenous infusion on Day 0. |
|
|
| Primary | Severity of Local Adverse Events (AEs) | The severity of local AEs was graded using the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Clinical Trials. Grade 1: Pain = does not interfere with activity; Tenderness = mild discomfort to touch; Erythema/Redness = 2.5-5 cm; Induration/Swelling = 2.5-5 cm and does not interfere with activity. Grade 2: Pain = Repeated use of non-narcotic pain reliever > 24 hours or interferes with daily activity; Tenderness = Discomfort with movement; Erythema/Redness = 5.1-10 cm; Induration/Swelling = 5.1-10 cm and interferes with activity. Grade 3: Pain = Any use of narcotic pain reliever or prevents daily activity; Tenderness = Significant discomfort at rest; Erythema/Redness = > 10 cm; Induration/Swelling = > 10 cm or prevents daily activity. Grade 4: Pain = Emergency room (ER) visit or hospitalization; Tenderness = ER visit or hospitalization; Erythema/Redness = Necrosis or exfoliative dermatitis; Induration/Swelling = Necrosis Grade 5: Death | The analysis included all participants in the dose escalation study. | Posted | Count of Participants | Participants | Within 7 days after the administration of CIS43LS |
|
|
|
| Primary | Participants With Systemic Adverse Events (AEs) | Participants with incidence of systemic adverse events occurring within 7 days after product administration of CIS43LS. Systemic reactogenicity events included fever, feeling unusually tired or unwell, muscle aches, headache, chills, nausea, and joint pain. | The analysis included all participants in the dose escalation study. | Posted | Count of Participants | Participants | Within 7 days after the administration of CIS43LS |
|
|
|
| Primary | Severity of Systemic Adverse Events (AEs) | The severity of systemic AEs occurring after the administration of CIS43LS was assessed using the grading scale below: Grade 1: Fever = 37.5^oC-37.9^oC; Fatigue, Headache, Myalgia = No interference with activity; Nausea = no interference with activity or 1-2 episodes/hour Grade 2: Fever = 38^oC-38.4^oC; Fatigue, Myalgia = Some interference with activity; Headache = Repeated use of non-narcotic pain reliever > 24 hours or some interference with activity; Nausea = Some interference with activity or > 2 episodes/24 hours Grade 3: Fever = 38.5^oC-39.5^oC; Fatigue = Prevents daily activity; Headache =Significant; any use of narcotic pain reliever or prevents daily activity; Myalgia =Significant; prevents daily activity; Nausea = Prevents daily activity, requires outpatient intravenous hydration Grade 4: Fever = > 39.5^oC; Fatigue, Headache, Myalgia = Emergency room (ER) visit or hospitalization; Nausea = ER visit or hospitalization for hypotensive shock Grade 5: Death | The analysis included all participants in the dose escalation study. | Posted | Count of Participants | Participants | Within 7 days after the administration of CIS43LS |
|
|
|
| Primary | Participants With Plasmodium Falciparum (Pf) Infection Detected by Microscopic Examination | Number of participants with Plasmodium falciparum (Pf) blood stage infection defined as blood smear-positive for Pf was assessed by microscopic examination of thick blood smear collected from participants from day 7 through week 24 (168 days) after administration of CIS43LS or placebo. Sample was collected every two weeks until week 24. | The analysis included all participants in the efficacy study. | Posted | Count of Participants | Participants | Day 7 through week 24 (168 days) after administration of intervention |
|
|
|
| Secondary | Participants With Plasmodium Falciparum (Pf) Infection Detected by Reverse Transcription Polymerase Chain Reaction (RT-PCR) | Number of participants with Plasmodium falciparum (Pf) blood stage infection defined as blood smear-positive for Pf was assessed by reverse transcription polymerase chain reaction (RT-PCR) using dried blood spot specimen collected from participants from day 21 through week 24 (168 days) after administration of CIS43LS or placebo. Sample was collected every two weeks until 24 weeks. Plasmodium 18S rRNA RT-PCR assay was applied to dried blood spots during analysis. | The analysis included all participants in the efficacy study. | Posted | Count of Participants | Participants | Day 21 through week 24 (168 days) after administration of intervention |
|
|
|
| Secondary | Maximum Serum Concentration (Cmax) for CIS43LS | Maximum serum concentration (Cmax) of CIS43LS by dose group following a single intravenous administration to assess durability of CIS43LS and allow for correlation with Plasmodium falciparum (Pf) infection risk. Cmax is the peak serum concentration that CIS43LS achieves after it has been administered. It is determined as a maximum value on the summary pharmacokinetic (PK) curve for each study group and measured by a Meso Scale Discovery LLC-based automation platform. | All participants who received CIS43LS, excluding placebo group. | Posted | Mean | Standard Deviation | µg/mL | Measured through Week 24 |
|
|
|
| Secondary | Time to Maximum Serum Concentration (Tmax) for CIS43LS | Time to maximum total serum concentration (Cmax) of CIS43LS by dose group following a single intravenous administration. Tmax is the time it takes to reach Cmax of CIS43LS after it has been administered; it is determined based on the summary PK curve for each dose group. This was calculated by subtracting the time the CIS43LS intravenous infusion was stopped from the time the blood was collected for the Cmax, at the post-one hour blood draw. | All participants who received CIS43LS, excluding placebo group. | Posted | Mean | Standard Deviation | Hours | One to 24 hours post-infusion |
|
|
|
| 0 |
| 6 |
| 0 |
| 6 |
| 4 |
| 6 |
| EG001 | Dose-escalation Study: Arm 2: 10 mg/kg of CIS43LS | Participants receive 10 mg/kg of CIS43LS as one time intravenous infusion on Day 0. | 0 | 6 | 0 | 6 | 5 | 6 |
| EG002 | Dose-escalation Study: Arm 3: 40 mg/kg of CIS43LS | Participants receive 40 mg/kg of CIS43LS as one time intravenous infusion on Day 0. | 0 | 6 | 0 | 6 | 4 | 6 |
| EG003 | Efficacy Study: Arm 1: 10 mg/kg of CIS43LS | Participants receive 10 mg/kg of CIS43LS as one time intravenous infusion on Day 0. | 1 | 110 | 1 | 110 | 49 | 110 |
| EG004 | Efficacy Study: Arm 2: 40 mg/kg of CIS43LS | Participants receive 40 mg/kg of CIS43LS as one time intravenous infusion on Day 0. | 0 | 110 | 1 | 110 | 40 | 110 |
| EG005 | Efficacy Study: Arm 3: Placebo | Participants receive placebo as one time intravenous infusion on Day 0. | 0 | 110 | 2 | 110 | 61 | 110 |
| Inguinal Hernia Repair | Surgical and medical procedures | Systematic Assessment |
|
| Umbilical Hernia Repair | Surgical and medical procedures | Systematic Assessment |
|
| Hypersplenism | Blood and lymphatic system disorders | Systematic Assessment |
|
| Lymphadenitis | Blood and lymphatic system disorders | Systematic Assessment |
|
| Neutropenia | Blood and lymphatic system disorders | Systematic Assessment |
|
| Bradycardia | Cardiac disorders | Systematic Assessment |
|
| Tachycardia | Cardiac disorders | Systematic Assessment |
|
| Eye Swelling | Eye disorders | Systematic Assessment |
|
| Visual Acuity Reduced | Eye disorders | Systematic Assessment |
|
| Abdominal Pain | Gastrointestinal disorders | Systematic Assessment |
|
| Abdominal Pain Lower | Gastrointestinal disorders | Systematic Assessment |
|
| Abdominal Pain Upper | Gastrointestinal disorders | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | Systematic Assessment |
|
| Dental Caries | Gastrointestinal disorders | Systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | Systematic Assessment |
|
| Dyspepsia | Gastrointestinal disorders | Systematic Assessment |
|
| Dysphagia | Gastrointestinal disorders | Systematic Assessment |
|
| Food Poisoning | Gastrointestinal disorders | Systematic Assessment |
|
| Gastric Disorder | Gastrointestinal disorders | Systematic Assessment |
|
| Gastric Ulcer | Gastrointestinal disorders | Systematic Assessment |
|
| Gastritis | Gastrointestinal disorders | Systematic Assessment |
|
| Gastrooesophageal Reflux Disease | Gastrointestinal disorders | Systematic Assessment |
|
| Gingival Pain | Gastrointestinal disorders | Systematic Assessment |
|
| Gingival Ulceration | Gastrointestinal disorders | Systematic Assessment |
|
| Haemorrhoids | Gastrointestinal disorders | Systematic Assessment |
|
| Mouth Ulceration | Gastrointestinal disorders | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | Systematic Assessment |
|
| Proctalgia | Gastrointestinal disorders | Systematic Assessment |
|
| Strangulated Umbilical Hernia | Gastrointestinal disorders | Systematic Assessment |
|
| Toothache | Gastrointestinal disorders | Systematic Assessment |
|
| Umbilical Hernia | Gastrointestinal disorders | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | Systematic Assessment |
|
| Asthenia | General disorders | Systematic Assessment |
|
| Chest Discomfort | General disorders | Systematic Assessment |
|
| Chest Pain | General disorders | Systematic Assessment |
|
| Chills | General disorders | Systematic Assessment |
|
| Fatigue | General disorders | Systematic Assessment |
|
| Hernia Pain | General disorders | Systematic Assessment |
|
| Pyrexia | General disorders | Systematic Assessment |
|
| Swelling | General disorders | Systematic Assessment |
|
| Acarodermatitis | Infections and infestations | Systematic Assessment |
|
| Appendicitis | Infections and infestations | Systematic Assessment |
|
| Bronchitis | Infections and infestations | Systematic Assessment |
|
| Conjunctivitis | Infections and infestations | Systematic Assessment |
|
| Dysentery | Infections and infestations | Systematic Assessment |
|
| Furuncle | Infections and infestations | Systematic Assessment |
|
| Gastroenteritis | Infections and infestations | Systematic Assessment |
|
| Genital Infection | Infections and infestations | Systematic Assessment |
|
| Genitourinary Tract Infection | Infections and infestations | Systematic Assessment |
|
| Herpes Dermatitis | Infections and infestations | Systematic Assessment |
|
| Hordeolum | Infections and infestations | Systematic Assessment |
|
| Infection | Infections and infestations | Systematic Assessment |
|
| Laryngitis | Infections and infestations | Systematic Assessment |
|
| Localised Infection | Infections and infestations | Systematic Assessment |
|
| Malaria | Infections and infestations | Systematic Assessment |
|
| Paronychia | Infections and infestations | Systematic Assessment |
|
| Rhinitis | Infections and infestations | Systematic Assessment |
|
| Salmonellosis | Infections and infestations | Systematic Assessment |
|
| Sinobronchitis | Infections and infestations | Systematic Assessment |
|
| Tinea Pedis | Infections and infestations | Systematic Assessment |
|
| Tinea Versicolour | Infections and infestations | Systematic Assessment |
|
| Tonsillitis | Infections and infestations | Systematic Assessment |
|
| Typhus | Infections and infestations | Systematic Assessment |
|
| Urinary Tract Infection | Infections and infestations | Systematic Assessment |
|
| Wound Infection | Infections and infestations | Systematic Assessment |
|
| Injury | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Limb Injury | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Skin Abrasion | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Wound | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Alanine Aminotransferase Increased | Investigations | Systematic Assessment |
|
| Blood Creatinine Increased | Investigations | Systematic Assessment |
|
| Blood Pressure Diastolic Decreased | Investigations | Systematic Assessment |
|
| Blood Pressure Diastolic Increased | Investigations | Systematic Assessment |
|
| Blood Pressure Increased | Investigations | Systematic Assessment |
|
| Blood Pressure Systolic Decreased | Investigations | Systematic Assessment |
|
| Blood Pressure Systolic Increased | Investigations | Systematic Assessment |
|
| Platelet Count Decreased | Investigations | Systematic Assessment |
|
| White Blood Cell Count Decreased | Investigations | Systematic Assessment |
|
| White Blood Cell Count Increased | Investigations | Systematic Assessment |
|
| Decreased Appetite | Metabolism and nutrition disorders | Systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Back Pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Intervertebral Disc Protrusion | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Myalgia | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Pain In Extremity | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Torticollis | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Dizziness | Nervous system disorders | Systematic Assessment |
|
| Head Discomfort | Nervous system disorders | Systematic Assessment |
|
| Headache | Nervous system disorders | Systematic Assessment |
|
| Paraesthesia | Nervous system disorders | Systematic Assessment |
|
| Sciatica | Nervous system disorders | Systematic Assessment |
|
| Tremor | Nervous system disorders | Systematic Assessment |
|
| Dysuria | Renal and urinary disorders | Systematic Assessment |
|
| Breast Pain | Reproductive system and breast disorders | Systematic Assessment |
|
| Menorrhagia | Reproductive system and breast disorders | Systematic Assessment |
|
| Metrorrhagia | Reproductive system and breast disorders | Systematic Assessment |
|
| Vaginal Discharge | Reproductive system and breast disorders | Systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Oropharyngeal Pain | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Respiratory Disorder | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Rhinorrhoea | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Dermatitis Contact | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Pruritus | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Urticaria | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Tooth Extraction | Surgical and medical procedures | Systematic Assessment |
|
| Venipuncture | Surgical and medical procedures | Systematic Assessment |
|
| Hypertension | Vascular disorders | Systematic Assessment |
|
| Hypotension | Vascular disorders | Systematic Assessment |
|
| Thrombophlebitis | Vascular disorders | Systematic Assessment |
|
Not provided
Not provided
| D000079426 |
| Vector Borne Diseases |
| Title | Measurements |
|---|---|
|
| Grade 3 |
|
| Grade 4 |
|
| Grade 5 |
|
| Title | Measurements |
|---|---|
|
| Muscle aches |
|
| Headache |
|
| Chills |
|
| Nausea |
|
| Joint pain |
|
| Title | Measurements |
|---|---|
|
| Grade 3 |
|
| Grade 4 |
|
| Grade 5 |
|